1. A method for determining the likelihood of a patient responding to treatment with a VEGF antagonist, where the method includes: (a) detecting the expression of at least one of the following genes: DLL4, angiopoietin 2 (Angpt2), NOS2, factor V, factor VIII (AHF ), EGFL7, EFNA3, PGF, ANGPTL1, SELP, Cox2, fibronectin (FN_EIIIB), ESM1 and stromal growth factor (SDF1) in a biological sample obtained from a patient prior to any administration of a VEGF antagonist to a patient； (b) comparison of expression level by at least one gene with a reference expression level of at least one gene, where the expression level of at least one gene in the patient’s sample relative to the reference level identifies the patient who is likely to respond to treatment with a VEGF antagonist, and (c) informing the patient that he is more likely to be susceptible to treatment with a VEGF antagonist .2. A method for optimizing the therapeutic efficacy of anti-cancer therapy for a patient, the method comprising: (a) detecting the expression of at least one of the following genes: DLL4, angiopoietin 2 (Angpt2), NOS2, factor V, factor VIII (AHF), EGFL7, EFNA3, PGF, ANGPTL1, SELP, Cox2, fibronectin (FN_EIIIB), ESM1 and stromal growth factor (SDF1) in a biological sample obtained from a patient prior to any administration of a VEGF antagonist to a patient； (b) comparing the expression level of at least one gene with a reference the level of expression of at least one gene, where according to the change in the level of exp resression of at least one gene in a patient’s sample relative to a reference level identifies a patient who is likely to respond to treatment with a VEGF antagonist, and (c) advising the patient that anti-cancer therapy should include a VEGF antagonist. 3. Method m1. Способ определения, с какой вероятностью пациент будет реагировать на лечение антагонистом VEGF, где способ включает:(a) обнаружение экспрессии по меньшей мере одного из следующих генов: DLL4, ангиопоэтина 2 (Angpt
